A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors

MC #23-18

NCT #
Condition(s)
Anal Cancer, Breast Cancer, Colorectal Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), osteosarcoma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor
Molecular Target(s)
TROP2
Drug Classification(s)
Antibody Drug Conjugate
Agents(s)
Adagrasib is a potent, highly selective and orally available small molecule inhibitor of a form of KRAS that harbors an oncogenic substitution mutation (G12C).mutation (G12C).
Phase(s)
I/II

Mechanism of Action

LCB84 is an anti-TROP2 ADC

Purpose

  • How much of the study agent can be given alone or in combination with Pembrolizumab with an acceptable level of side effects
  • The effects of the study agent alone or in combination with Pembrolizumab (good and bad)
  • How much of the study agent is absorbed into the blood and how fast it is removed
  • If research tests can be used in the future to predict who will benefit from LCB84
  • How the study agent is acting on your body

Location

Mary Crowley Cancer Research - Medical City Dallas

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.

7777 Forest Lane,
Building C-707
Dallas, TX 75230

972.566.3000